Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

INmune Bio Inc. (NASDAQ: INMB) (the 'Company”), a clinical-stage inflammation and immunology company, today announced that it ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and ...

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent ...

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Barcelona’s blood and tissue bank says it has developed a new system for the large-scale production of mesenchymal stromal cells.

This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...

Epithelial-to-mesenchymal transition (EMT), a complex biological pathway that facilitates cellular plasticity, is used by tumor cells to enable metastasis and drug resistance. Our functional ...